Search PubMedSearch

Biomedical subjects

Jason S Carroll

Publications and source records attributed to Jason S Carroll.

2 recordsLinked to original sources

The transcription factor BACH1 couples chromatin priming and repression to enable macrophage plasticity and adaptation.

Macrophage activation and tissue adaptation involve precise transcriptional control by lineage-determining transcription factors (LDTFs) and stimulus-dependent TFs. The heme-regulated transcriptional repressor BACH1 clusters with myeloid LDTFs in unstimulated macrophages, suggesting a role in shaping macrophage identity and function. We found that BACH1 bound to both inactive and active regulatory regions, including latent enhancers. BACH1 recruited the NuRD complex and had dual functions, establishing early chromatin accessibility while actively repressing transcription. Upon inflammatory stimulation, BACH1 rapidly redistributed in cis to nearby promoters, reshaping chromatin occupancy, motif specificity, and enhancer-promoter interactions. BACH1 constrained 3D chromatin architecture, limiting enhancer mobility and TF complex dynamics. In vivo, Bach1 deletion impaired macrophage polarization and tissue adaptation and limited resilience during systemic and regenerative inflammation. Thus, BACH1 acts as an early chromatin accessibility-priming factor while actively repressing transcription-a regulatory activity that can be defined as pioneer repression-thereby shaping the macrophage epigenome in response to inflammatory and tissue contexts.

Basic-Leucine Zipper Transcription Factors

Why do we continue to have an incomplete understanding of estrogen receptor(s) actions in cancer systems?

The topic proposed asks why we have an incomplete understanding of estrogen receptor (ER) action in cancer. We agree that the role of ER in some cancers is poorly understood, but the role of ER in luminal breast cancer (which represents the biggest subtype of the most common cancer in women) is very well characterised. Although technologies evolve and allow us to learn more about the intricacies of the genome and the multitude of ways breast cancer can adapt to bypass treatments, our understanding of how ER regulates gene expression is extraordinary. We would posit that the key events in ER-mediated cell cycle progression are already known and although new information adds granular information to our paradigms of ER action, we need to better characterise what has been discovered already.

Humans